Skip to main content
Back
Watch Compare

X4 Pharmaceuticals, Inc

Data quality: 100%
XFOR
NASDAQ Manufacturing Chemicals
$4.22
▲ $0.02 (0.36%)
6 months return
—
Momentum
Neutral
ROE
-241.50%

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)154.20%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-241.50%
Below sector avg (-54.47%)
ROIC-61.75%
Net Margin-1218.45%
Op. Margin-1336.66%

Safety

Debt / Equity
1.22
Above sector avg (0.30)
Current Ratio5.65
Interest Coverage-9.79

Valuation

PE (TTM|NTM)
-4.65 | -4.25
Below sector avg (-1.50)
P/B Ratio5.98
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -85.62 M

Price History

Financial Trends

Analyst Price Target

3 analysts
Buy
+176.8%
upside to target
Current
$4.22
Consensus Target
$11.67
$10.00
Low
$13.00
High
Forecast
Forward P/E
-4.25
Forward EPS
-$0.97
Est. Revenue
6.90 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.20 · Rev Est: 3.20 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported $0.04 -$3.47 -$0.69 -$0.22 — —
Estimate -$3.75 -$4.34 -$0.84 -$0.35 -$0.20 -$0.21
Surprise +101.07% +19.98% +18.18% +36.69% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) 154.20% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -241.50% · Net Margin: -1218.45%
Revenue (TTM) 6.50 M Net Income (TTM) -79.20 M
ROE -241.50% ROA -58.94%
Gross Margin N/A Operating Margin -1336.66%
Net Margin -1218.45% Free Cash Flow (TTM) -85.62 M
ROIC -61.75% FCF Growth (3Y) N/A

Safety

D/E: 1.22 · Current: 5.65
Debt / Equity 1.22 Current Ratio 5.65
Interest Coverage -9.79 Asset Turnover 0.05
Working Capital 109.30 M Tangible Book Value 34.83 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -4.65 · EV/EBITDA: N/A
P/E Ratio -4.65 Forward P/E -4.25
P/B Ratio 5.98 P/S Ratio 56.65
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 53.37 Fwd Earnings Yield N/A
FCF Yield -23.25%
Market Cap 368.22 M Enterprise Value 373.59 M

Per Share

EPS: -1.87 · FCF/Share: -0.94
EPS (Diluted TTM) -1.87 Revenue / Share 0.07
FCF / Share -0.94 OCF / Share -0.94
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 108.10% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 108.10%
SBC-Adj. FCF -90.07 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 6.50 M 2.56 M — 0.0 0.0
Net Income -79.20 M -37.45 M -101.17 M -93.87 M -88.70 M
EPS (Diluted) -1.87 -0.19 -0.57 -1.52 —
Gross Profit — — — — —
Operating Income -86.88 M -36.40 M -107.52 M -87.57 M -85.11 M
EBITDA — — — — —
R&D Expenses 72.72 M 81.64 M 72.02 M 61.06 M 50.65 M
SG&A Expenses — — — — —
D&A 1.28 M 796,000.0 419,000.0 513,000.0 499,000.0
Interest Expense 8.88 M 8.77 M 5.78 M 3.99 M 3.64 M
Income Tax 41,000.0 310,000.0 78,000.0 28,000.0 17,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 290.46 M 146.45 M 147.26 M 155.59 M 117.18 M
Total Liabilities 104.17 M 124.30 M 96.16 M 81.54 M 52.76 M
Shareholders' Equity 186.29 M 22.15 M 51.10 M 74.05 M 64.41 M
Total Debt 75.00 M 75.00 M 55.00 M 32.50 M 32.50 M
Cash & Equivalents 217.05 M 55.70 M 99.22 M 121.72 M 81.79 M
Current Assets 261.58 M 112.18 M 122.08 M 128.68 M 87.88 M
Current Liabilities 25.76 M 32.88 M 22.86 M 22.32 M 14.02 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -4.7 -1.5
P/B 6.0 1.6
ROE % -241.5 -54.5
Net Margin % -1218.5 -41.5
Rev Growth 5Y % — 1.7
D/E 1.2 0.3